Lu-177 DOTATATE for non-gastrointestinal neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a radioactive treatment (Lutathera) for people with certain neuroendocrine tumors (NETs) that are not in the stomach or intestines)Skip to content
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a well-differentiated neuroendocrine tumor (NET) that is not in the stomach or intestines (non-GEP), and it cannot be removed by surgery or has spread to other parts of the body. Or, if you have a GEP NET, you must have had PRRT before and it's been more than 18 months since that treatment started.
- Your tumor must show growth on imaging (CT or MRI) — you need scans showing this, with the most recent within the last 6 weeks and an older scan within the last 3 years.
- The tumor must show high uptake on a special scan (OctreoScan or Ga68 Dotatate PET) — at least as high as the normal liver.
- You must be generally well enough to have a performance status (KPS) of at least 60 (meaning you can care for yourself and are active).
- Your kidney and liver function must be within acceptable limits (creatinine clearance at least 40 mL/min, blood counts not too low, bilirubin and albumin levels okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
Hear when a new Paraganglioma/ Phaeochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.